Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary for 2.1.1.67 extracted from

  • Xin, H.W.; Fischer, C.; Schwab, M.; Klotz, U.
    Thiopurine S-methyltransferase as a target for drug interactions (2005), Eur. J. Clin. Pharmacol., 61, 395-398.
    View publication on PubMed
Search for more literature for 2.1.1.67

Inhibitors

Inhibitors Comment Organism Structure
Azathioprine IC50: 0.43-0.532 mM Homo sapiens
Furosemide IC50: 0.015-0.019 mM, has the potential to inhibit thiopurine S-methyltransferase in patients with chronic inflammatory bowel disease Homo sapiens
piretanide IC50: 0.3-0.313 mM Homo sapiens
testosterone IC50: 0.03-0.072 mM Homo sapiens

Organism

Organism UniProt Comment Textmining
Homo sapiens
-
-
-

Source Tissue

Source Tissue Comment Organism Textmining
erythrocyte from patients with chronic inflammatory bowel disease Homo sapiens
-

Substrates and Products (Substrate)

Substrates Comment Substrates Organism Products Comment (Products) Rev. Reac.
S-adenosyl-L-methionine + 6-thioguanine
-
 Homo sapiens S-adenosyl-L-homocysteine + 6-methylthioguanine
-
 ?

Synonyms

Synonyms Comment Organism
TPMT
-
 Homo sapiens

IC50 Value

IC50 Value IC50 Value Maximum Comment Organism Inhibitor Structure
0.015 0.019 IC50: 0.015-0.019 mM, has the potential to inhibit thiopurine S-methyltransferase in patients with chronic inflammatory bowel disease Homo sapiens Furosemide
0.03 0.072 IC50: 0.03-0.072 mM Homo sapiens testosterone
0.3 0.313 IC50: 0.3-0.313 mM Homo sapiens piretanide
0.43 0.532 IC50: 0.43-0.532 mM Homo sapiens Azathioprine